WGb-0301

N/A

Report date: 2026/01/14 20:00:44

Base Information

Drug NameWGb-0301

Drug Alias NameWGb-0301

ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNPCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesSichuan University West China Hospital Of Sichuan University

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A